{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:13:40Z","timestamp":1790802820289,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["NSW 2113"],"award-info":[{"award-number":["NSW 2113"]}],"id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacadv.2025.102304","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T08:00:51Z","timestamp":1762588851000},"page":"102304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes"],"prefix":"10.1016","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1650-0205","authenticated-orcid":false,"given":"Anne T.","family":"Reutens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulari Hakamuwa","family":"Lekamlage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agus","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray D.","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2025.102304_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib4","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of sglt2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: emperor- preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib8","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib9","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102304_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the empa-reg outcome trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2025.102304_bib11","doi-asserted-by":"crossref","first-page":"e032463","DOI":"10.1161\/JAHA.123.032463","article-title":"Potential mediators for treatment effects of novel diabetes medications on cardiovascular and renal outcomes: a meta-regression analysis","volume":"13","author":"Rodriguez-Valadez","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.102304_bib12","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/cvr\/cvad122","article-title":"Genetic variation in solute carrier family 5 member 2 mimicking sodium-glucose co-transporter 2- inhibition and risk of cardiovascular disease and all-cause mortality: reduced risk not explained by lower plasma glucose","volume":"119","author":"Bechmann","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacadv.2025.102304_bib13","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the empa-reg outcome study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2025.102304_bib14","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/dom.15586","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on inflammatory biomarkers: a meta-analysis of randomized controlled trials","volume":"26","author":"Buttice","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with hfref: from the empa-tropism study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102304_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: Sglt2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"J Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of sglt2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacadv.2025.102304_bib18","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0735-1097(92)90167-L","article-title":"The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure","volume":"20","author":"Packer","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study ii (Cibis-ii): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2025.102304_bib21","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib22","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/HYPERTENSIONAHA.122.19177","article-title":"Dapagliflozin attenuates sympathetic and pressor responses to stress in young prehypertensive spontaneously hypertensive rats","volume":"79","author":"Kim","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2025.102304_bib23","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1007\/s00125-020-05145-0","article-title":"Empagliflozin modulates renal sympathetic and heart rate baroreflexes in a rabbit model of diabetes","volume":"63","author":"Gueguen","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacadv.2025.102304_bib24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jash.2017.07.005","article-title":"The effect of empagliflozin on muscle sympathetic nerve activity in patients with type ii diabetes mellitus","volume":"11","author":"Jordan","year":"2017","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.jacadv.2025.102304_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022637","article-title":"Different responses of muscle sympathetic nerve activity to dapagliflozin between patients with type 2 diabetes with and without heart failure","volume":"10","author":"Hamaoka","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.102304_bib26","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ekir.2023.08.036","article-title":"Randomized trial comparing sglt2 inhibition and hydrochlorothiazide on sympathetic traffic in type 2 diabetes","volume":"8","author":"Heusser","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.jacadv.2025.102304_bib27","doi-asserted-by":"crossref","first-page":"285s","DOI":"10.1042\/cs063285s","article-title":"Radiotracer methodology for the simultaneous estimation of total, and renal, sympathetic nervous system activity in humans","volume":"63","author":"Esler","year":"1982","journal-title":"Clin Sci"},{"key":"10.1016\/j.jacadv.2025.102304_bib28","doi-asserted-by":"crossref","first-page":"311s","DOI":"10.1042\/cs059311s","article-title":"Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension","volume":"59","author":"Esler","year":"1980","journal-title":"Clin Sci"},{"key":"10.1016\/j.jacadv.2025.102304_bib29","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.2337\/db12-0138","article-title":"Neuroadrenergic dysfunction along the diabetes continuum: a comparative study in obese metabolic syndrome subjects","volume":"61","author":"Straznicky","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jacadv.2025.102304_bib30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1046\/j.1365-201X.2003.01089.x","article-title":"Sympathetic nerve activity and neurotransmitter release in humans: translation from pathophysiology into clinical practice","volume":"177","author":"Esler","year":"2003","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.jacadv.2025.102304_bib31","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0773.1993.tb00579.x","article-title":"Clinical application of noradrenaline spillover methodology: delineation of regional human sympathetic nervous responses","volume":"73","author":"Esler","year":"1993","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.jacadv.2025.102304_bib32","first-page":"E21","article-title":"Measurement of total and organ-specific norepinephrine kinetics in humans","volume":"247","author":"Esler","year":"1984","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/cs0620247","article-title":"Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics","volume":"62","author":"Esler","year":"1982","journal-title":"Clin Sci"},{"key":"10.1016\/j.jacadv.2025.102304_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/01.HYP.16.2.121","article-title":"Evidence for increased renal norepinephrine overflow during sodium restriction in humans","volume":"16","author":"Friberg","year":"1990","journal-title":"Hypertension"},{"key":"10.1016\/j.jacadv.2025.102304_bib35","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s00125-020-05254-w","article-title":"Increase in endogenous glucose production with sglt2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy","volume":"63","author":"Daniele","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacadv.2025.102304_bib36","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1475-2840-13-28","article-title":"The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus","volume":"13","author":"Cherney","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacadv.2025.102304_bib37","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1210\/clinem\/dgac617","article-title":"Effect of dapagliflozin on cardiac function and metabolic and hormonal responses to exercise","volume":"108","author":"Herring","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib38","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/0024-3205(79)90371-0","article-title":"Determination of norepinephrine apparent release rate and clearance in humans","volume":"25","author":"Esler","year":"1979","journal-title":"Life Sci"},{"key":"10.1016\/j.jacadv.2025.102304_bib39","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose- regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the dapasalt trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2025.102304_bib42","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacadv.2025.102304_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: a randoSzed, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.jacadv.2025.102304_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2021.101304","article-title":"Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: an active-controlled randomised trial","volume":"48","author":"Breder","year":"2022","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib45","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the empire hf trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102304_bib47","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib48","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13340-020-00474-2","article-title":"Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation","volume":"12","author":"Yamada","year":"2021","journal-title":"Diabetol Int"},{"key":"10.1016\/j.jacadv.2025.102304_bib49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ejhf.2121","article-title":"Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure","volume":"23","author":"Miller","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102304_bib50","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2024.02.028","article-title":"Sglt2 inhibition: neither a diuretic nor a natriuretic","volume":"83","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003594","article-title":"Intracardiac pressures measured using an implantable hemodynamic monitor","volume":"10","author":"Zile","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacadv.2025.102304_bib52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical analysis of the effects of sglt2 inhibitors on renal tubular sodium, water and chloride homeostasis and their role in influencing heart failure outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2024.02.020","article-title":"Water conservation overrides osmotic diuresis during sglt2 inhibition in patients with heart failure","volume":"83","author":"Marton","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib54","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the emperor-preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib55","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1161\/01.CIR.0000103123.66264.FE","article-title":"Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension","volume":"108","author":"Huggett","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2025.102304_bib56","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/oby.20614","article-title":"The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia","volume":"22","author":"Straznicky","year":"2014","journal-title":"Obesity"},{"key":"10.1016\/j.jacadv.2025.102304_bib57","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fphys.2016.00516","article-title":"Comparable attenuation of sympathetic nervous system activity in obese subjects with normal glucose tolerance, impaired glucose tolerance, and treatment na\u00efve type 2 diabetes following equivalent weight loss","volume":"7","author":"Straznicky","year":"2016","journal-title":"Front Physiol"},{"key":"10.1016\/j.jacadv.2025.102304_bib58","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1523\/JNEUROSCI.23-14-05998.2003","article-title":"Role of melanocortin-4 receptors in mediating renal sympathoactivation to leptin and insulin","volume":"23","author":"Rahmouni","year":"2003","journal-title":"J Neurosci"},{"key":"10.1016\/j.jacadv.2025.102304_bib59","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13300-018-0480-7","article-title":"Effect of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale","volume":"9","author":"Kubota","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacadv.2025.102304_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacadv.2025.102304_bib61","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do sglt2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacadv.2025.102304_bib62","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"issue":"6 Pt 2","key":"10.1016\/j.jacadv.2025.102304_bib63","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/01.HYP.19.6.628","article-title":"Plasma norepinephrine responses to head-up tilt are misleading in autonomic failure","volume":"19","author":"Meredith","year":"1992","journal-title":"Hypertension"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:05:45Z","timestamp":1771358745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25007331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772963X25007331"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102304","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102304"}}